← Eichor
Condition: Clinical Stage Iii Gastroesophageal Junction Adenocarcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Clinical Stage Iii Gastroesophageal Junction Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma
Phase 3 · 1 location(s) · Biotech Pharmaceutical Co., Ltd. · NCT05978050Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients Wi
Phase 2/Phase 3 · 10 location(s) · Beijing Biostar Pharmaceuticals Co., Ltd. · NCT06841679A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenoca
Phase 3 · 6 location(s) · Akeso · NCT07023315Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocar
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06163729CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or G
Phase 1 · 1 location(s) · Roswell Park Cancer Institute · NCT04511039Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemo
Phase 3 · 106 location(s) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07385703Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Meta
Phase 3 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07152405SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or M
Phase 3 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT06649292mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · 794 location(s) · Alliance for Clinical Trials in Oncology · NCT05677490JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophagea
Phase 3 · 1 location(s) · NingBo Junyan Hongshi Biosciences Co., Ltd · NCT07584135Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanc
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT05651594Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
Phase 2 · 3 location(s) · Mayo Clinic · NCT06078709Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07277439Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Phase 3 · 96 location(s) · NRG Oncology · NCT03801876A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Posit
Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07518147Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal J
Phase 2 · 1 location(s) · Zekuan Xu · NCT06461910Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT04615013Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Phase 2/Phase 3 · 374 location(s) · National Cancer Institute (NCI) · NCT06203600
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.